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test, Wilcoxon test, Chi-square test) were: number of patients exposed to allogeneic 
red cells, amount of blood transfusions, and the number of length of stay in hospital. 
An economic model was quantified the cost saving of EVICEL® in ICH. Results: 
preliminary results showed that application of EVICEL reduce number of transfused 
RBC, postoperative haemoglobin loss, and days of hospital stay. In the hospital cost. 
analysis EVICEL® predicts resource reduction with average cost-savings of € 1.227 
per patient. ConClusions: Overall, the results suggest that EVICEL are efficacious 
in reducing both post-operative blood loss, and hospital stay The protocol with 
EVICEL® produce clinical appropriateness and important cost savings for hospital.
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objeCtives: A pilot project concerning the evaluation of potential cost-saving for 
switching from chemotherapy (rituximab) intravenous injection (IV) to chemother-
apy subcutaneous injection (SC) at national level in France” was selected to demon-
strate added benefits beyond clinical effectiveness. Methods: To define the added 
value of rituximab SC injection improvement a 5-step methodology was defined as 
follow: 1) Define the key value drivers (cost/benefits), 2) Implement decision tree, 
3) Estimate the associated patient flow, 4) Evaluate the direct and indirect costs of 
patient flow including hospital and insurance perspectives, 5) Communication to the 
stakeholders. For rituximab SC injection versus rituximab IV injection the decision 
tree model was developed using the French health care with rituximab marketing 
authorizations. Epidemiologic data were estimated with internal market share data 
and the French health watch institute. Results: Four main benefits emerged at 
national level; (i) A reduction in staff time was observed for nurses, pharmacists and 
technicians leading to a potential saving at 300 000€ per year. (ii) A potential saving 
of 500 000€ per year was observed for the reduction in consumables. (iii) The shorter 
occupancy of chair for SC injection was leaded to a potential saving of 700 000€ 
per year. (iv) Reduction in wastage was 300 000€ per year thanks to sub-cutaneous 
injection. ConClusions: Results showed that cost-saving from switching for IV 
to SC exist. Other potential benefits should be investigated to demonstrate all value 
of medicine product. Therefore, a quality of life study is planned to demonstrate 
potential added value of rituximab SC vs. rituximab IV in France. Cost-effectiveness 
study should be also performed to demonstrate potential cost saving per quality 
adjusted life year.
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objeCtives: Alpha-1 antitrypsin deficiency (AATD) is a rare, under-diagnosed disease 
that may predispose an individual to chronic obstructive pulmonary disease (COPD) 
early in life. Affected individuals often undergo long delays between symptomatology 
and diagnosis, and are commonly treated like standard COPD patients before receiv-
ing proper treatment with expensive AAT inhibitors. Recognizing the differences 
between these conditions may speed identification of AATD patients and prevent mis-
diagnosis. This study’s objective was to define differences between individuals with 
AATD and non-AATD associated COPD. Methods: Patient demographics, emergency 
room (ER) and inpatient visits, and costs (ER, inpatient, outpatient) between AATD and 
COPD patients were assessed using 2011-2013 Medicare data. ER and inpatient visits, 
and costs were assessed during a 1-year post period following confirmed COPD or 
AATD diagnosis. Results: Mean age of COPD (n= 183,832) and AATD (n= 279) cohorts 
were 72.6±11.3 and 64.6±11.7 years, respectively (p< 0.001). Among COPD patients, 
20.3% were receiving disability benefits, which was significantly less than AATD 
patients (40.1%; p< 0.001). COPD mean Charlson Comorbidity Index (CCI) score was 
3.7±2.7, while AATD was 2.4±2.0 (p< 0.001). AATD patients had more ER (58.4%) and 
inpatient (58.0%) visits than COPD patients (42.5% and 19.5%, respectively; p< 0.001). 
Despite the fact that only 13% of AATD patients were receiving AAT inhibitors, AATD 
total healthcare costs (per patient) were still $27,674 greater than COPD total costs 
(p< 0.001). ConClusions: Our results show that even though our AATD Medicare 
patients are younger and have lower CCI scores, they experience more ER and inpa-
tient visits, and cost more to the healthcare system compared to older, less healthy 
COPD patients. Identifying the medical burden of AATD, raises attention to the need 
for an effective screening tool for identifying AATD patients among those who have 
COPD as well as better understanding AATD disease progression.
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objeCtives: The aim of the longitudinal multicenter study is to estimate the eco-
nomic impact of employment status on the social cost of a patient submitted to 
bariatric surgery techniques. Methods: Individual socio-economic and clinical 
data have been collected for adult patients in charge to 6 Hospital in Italy at time 
of intervention of gastric banding, gastric by-pass and sleeve gastrectomy and fol-
lowed up to 1 year. Direct medical costs were estimated using tariffs for laboratory 
tests, diagnostic exams, visits, and prices for drugs. Procedure and inpatient cost 
data were collected at Center level. Non medical costs included costs for travel and 
accommodation, domestic help and informal care. The human capital approach 
has been used for estimating the loss of productivity of patients. The incremen-
tal effects of employment status on social cost were estimated by multivariate 
scenario, with adoption of the most persistent biologic (ustekinumab), can lead to 
valuable savings through lower cost of maintenance phase, avoided re-inductions, 
and reduced visits.
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objeCtives: Rare diseases such as ulcerative colitis (UC) have significant impact 
on patients and their families, as well as the healthcare systems and societies. 
The high costs of medicines makes actual researches in this field. The main aim 
of this study was to perform budget impact analysis of using combination of bio-
logics - infliximab + golimumab in equal proportions. Methods: Analysis of the 
published clinical trials was conducted to evaluate comparative efficacy and safety 
of the using of different types of biologics therapies – infliximab, golimumab. To 
measure costs of ulcerative colitis for the state budget were used “cost of illness” 
and “budget impact” analyses. Direct medical costs included diagnosis, treatments, 
medications, blood and its components, nutrient mixture and were calculated for 
1 year-therapy. In this study were performed 2 variants of UC treatment costs, in 
1st variant was used infliximab, in 2nd variant - infliximab + golimumab in equal 
proportions. Results: According to published trials golimumab was provided effi-
cacy similar to infliximab in inducing and maintaining clinical remission, clinical 
response, and mucosal healing. Loss of response was occurred in approximately 
30% of patients, leading to discontinuation of biologic therapy and/or colectomy. 
So using the combination of biologics was preferred. The mean annual overall 
direct health care cost of UC treatment for 1 patient with infliximab was esti-
mated to be 456 000 rubles ($ 8 514), and with infliximab + golimumab in equal 
proportions – 533 256 rubles ($9 957). Thus budget impact of using combination 
of 2 biologics - infliximab + golimumab in equal proportions was estimated to be 
14%. ConClusions: Golimumab was provided efficacy similar to infliximab and 
the use combination of 2 biologics infliximab + golimumab in equal proportions 
for treatment UC has little effect on the budget.
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objeCtives: to assess the cost effectiveness of the application of darbepoetin alfa 
vs other erythropoiesis-stimulating agents for anemia correction in patients on 
hemodialysis or peritoneal dialysis. Methods: The pharmacoeconomic model, 
providing the construction of decision tree, under which patients are treated by 
different ESP to achieve various levels of hemoglobin, was designed. To assess of 
the dosing schedule actual practice in the Russian healthcare system was perform 
a retrospective observational study (date from the 11 hospitals of Russia). The 
main method of pharmacoeconomic analysis was “cost-consequence” method 
and the analysis of the “impact on the budget”. A multivariant sensitivity analysis 
of the model relative to the cost of darbepoetin alfa ± 10 %, relative to the dose 
of darbepoetin alfa reduction at a level of 20 % and 47 % (based expert data) and 
relative to changes in hospitalization costs was performed. Results: The data 
on actual practice of darbepoetin alfa dossage in Russia indicate on a possible 
reduction of the dose during treatment an average of 47%. The total economy of 
budget per year (with respect to 1 patient) to hemodialysis patients may reach 
from 223,6 $ (for target hemoglobin values 11 (± 1) g/dL) to 616,47 $ (for hemo-
globin values 9 (± 1) g/dL). The total economy of budget per year for patients on 
peritoneal dialysis may reach from 216,32 $ (for 11 (± 1) g/dL) to 345,41 $ (for 
9 (± 1) g/dl). ConClusions: The darbepoetin alfa application for anemia cor-
rection in patients on hemodialysis or peritoneal dialysis is more cost-effective 
treatment option compared with other alternative erythropoiesis-stimulating 
drugs.
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objeCtives: Blood transfusion and hemostasis are becoming an important aspect 
of preoperative planning and intraoperative decision making in orthopaedic sur-
gery. Total hip arthroplasty (THA), place patients at risk of significant blood loss, 
which can result in the need for transfusion, risk of postoperative anemia and 
infection, and increase hospital stay. Humanitas Hospital (ICH) use a new protocol 
“without blood” perioperative strategies include the use of autologous blood dona-
tion and administration of erythropoietin; intraoperative measures include acute 
normovolemic hemodilution, anesthesia, use of tranexamic acid, intraoperative 
and postoperative blood salvage, specialized cautery, and a new topical hemostatic 
agents (EVICEL). Evicel is a fibrin sealant (fibrinogen and high concentration of 
thrombin) hemostatic agent, facilitates hemostasis, reduce the volume of blood 
loss in postoperative. The potential role and cost saving generated from use of 
EVICEL in the “protocol without blood” to control blood loss, number of avoid blood 
transfusions and reduction of length of hospital stay in patients undergoing THA 
revisions. Methods: was evaluated in a retrospective observational controlled 
study in patients undergoing THA revision: one group was treated with EVICEL and a 
control group with the same protocol but without EVICEL. The outcomes measured (t 
